share_log

Private Companies Are Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Biggest Owners and Were Hit After Market Cap Dropped CN¥581m

Private Companies Are Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Biggest Owners and Were Hit After Market Cap Dropped CN¥581m

私營企業是青島海爾生物醫藥股份有限公司(SHSE:688139)的最大股東,在市值下跌5.81億元后遭受打擊。
Simply Wall St ·  07/05 20:42

Key Insights

主要見解

  • Qingdao Haier BiomedicalLtd's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
  • A total of 4 investors have a majority stake in the company with 52% ownership
  • 21% of Qingdao Haier BiomedicalLtd is held by Institutions
  • 青島海爾生物醫療有限公司的顯着私有股權表明其關鍵決策受到來自更大公衆的股東的影響。
  • 該公司總計有4位投資者持有大部分股份,佔有52%的所有權。
  • 機構持有青島海爾生物醫療有限公司的21%股份。

A look at the shareholders of Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) can tell us which group is most powerful. We can see that private companies own the lion's share in the company with 41% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

觀察青島海爾生物醫療有限公司(上交所:688139)的股東可以告訴我們哪些群體最具影響力。我們可以看到,私人公司擁有該公司41%的股權。換句話說,該集團面臨最大的上行潛力(或下行風險)。

As a result, private companies as a group endured the highest losses last week after market cap fell by CN¥581m.

因此,在市值下跌58100萬元後,私人公司作爲一個群體遭受了最高的損失。

Let's take a closer look to see what the different types of shareholders can tell us about Qingdao Haier BiomedicalLtd.

讓我們仔細看看不同類型的股東告訴我們關於青島海爾生物醫療有限公司的信息。

ownership-breakdown
SHSE:688139 Ownership Breakdown July 6th 2024
SHSE: 688139所有權分佈2024年7月6日

What Does The Institutional Ownership Tell Us About Qingdao Haier BiomedicalLtd?

機構持股告訴我們有關青島海爾生物醫療有限公司的什麼信息?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見的指數回報進行比較。因此,他們通常會考慮購買包括在相關基準指數中的較大公司。

Qingdao Haier BiomedicalLtd already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Qingdao Haier BiomedicalLtd, (below). Of course, keep in mind that there are other factors to consider, too.

青島海爾生物醫療有限公司已有機構佔有股份。事實上,他們擁有公司中相當的股份。這意味着那些機構的分析師已經研究過股票並喜歡它。但就像其他人一樣,他們可能是錯誤的。如果兩個大型機構投資者同時嘗試出售股票,常見的情況是看到大幅股價下跌。因此,值得檢查青島海爾生物醫療有限公司的過去收益軌跡(如下所示)。當然,記住還有其他因素需要考慮。

earnings-and-revenue-growth
SHSE:688139 Earnings and Revenue Growth July 6th 2024
SHSE: 688139盈利和營業收入增長2024年7月6日

Hedge funds don't have many shares in Qingdao Haier BiomedicalLtd. Haier Group Corporation is currently the largest shareholder, with 32% of shares outstanding. For context, the second largest shareholder holds about 10% of the shares outstanding, followed by an ownership of 6.2% by the third-largest shareholder.

對於青島海爾生物醫療有限公司,對沖基金沒有太多股份。海爾集團是目前最大的股東,持有32%的流通股。爲了獲得背景信息,第二大股東持有流通股的約10%,第三大股東持有6.2%的股份。

Our research also brought to light the fact that roughly 52% of the company is controlled by the top 4 shareholders suggesting that these owners wield significant influence on the business.

我們的研究還揭示了一件事實,即約52%的公司由前四大股東控制,表明這些股東對公司具有重要的影響力。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

研究機構持股情況是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以取得相同的結果。相當多的分析師涵蓋了這筆股票,所以你可以很容易地調查預測增長。

Insider Ownership Of Qingdao Haier BiomedicalLtd

青島海爾生物醫療有限公司內部所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間是不同的。我們的數據反映了個別內部人員,至少捕捉到了董事會成員。公司管理業務,但首席執行官即使是董事會成員也必須向董事會負責。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。

Our most recent data indicates that insiders own less than 1% of Qingdao Haier Biomedical Co.,Ltd. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around CN¥6.2m worth of shares (at current prices). It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.

我們最新的數據表明,內部人士持有青島海爾生物醫療有限公司股份不到1%。但是,我們注意到,內部人士可能通過私人公司或其他公司結構間接持有利益。這是一個相當大的公司,所以董事會成員可以擁有公司的實際利益,而沒有持有太大的比例。在這種情況下,他們持有約CN¥620萬元的股票(按當前價格計算)。看到至少有一些內部所有權總是不錯的,但檢查這些內部人員是否一直在出售股票可能是有價值的。

General Public Ownership

一般大衆所有權

With a 22% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Qingdao Haier BiomedicalLtd. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

憑藉22%的所有權,普通公衆,主要包括個人投資者,對青島海爾生物醫療有限公司具有一定的影響力。雖然擁有這種所有權的大小可能不足以在他們的喜好中影響決策,但他們仍然可以對公司政策產生集體影響。

Private Equity Ownership

股權投資公司持有8.8%的股份,有能力參與塑造以價值創造爲重點的公司策略。一些投資者可能會因此而受到鼓舞,因爲股權投資公司有時可以鼓勵市場看到公司的價值,從而採取有益的策略。另外,那些持有者可能在將其上市後退出投資。

Private equity firms hold a 16% stake in Qingdao Haier BiomedicalLtd. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

股權投資公司持有青島海爾生物醫療有限公司16%的股份。這表明它們在關鍵的政策決策方面具有影響力。一些投資者可能會因此感到鼓舞,因爲私募股權有時能夠鼓勵有助於市場看到公司價值的策略。或者,這些持有者可能在公開上市後退出投資。

Private Company Ownership

私有公司的所有權

It seems that Private Companies own 41%, of the Qingdao Haier BiomedicalLtd stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

公開公司似乎擁有青島海爾生物醫療有限公司股票的41%。深入研究一下這一點可能值得。如果相關方,例如內部人士,在其中一傢俬營公司擁有利益,那麼應在年度報告中披露。私營公司可能還對該公司具有戰略利益。

Next Steps:

下一步:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Qingdao Haier BiomedicalLtd is showing 1 warning sign in our investment analysis , you should know about...

雖然考慮一個公司的不同股東群體是相當值得的,但還有其他更重要的因素。請注意,青島海爾生物工程有限公司在我們的投資分析中顯示了1個警示信號,您應該知道……

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但最終,決定該業務所有者將獲得多大利益的是未來而非過去。因此,我們認爲最好查看此免費報告,以了解分析師是否預測更光明的未來。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論